Dextromethorphan transdermal delivery device

Abstract

Provided herein are transdermal delivery devices comprising dextromethorphan. The transdermal delivery device can be characterized by the novel design, for example, with an adhesive layer and a reservoir layer, with an adhesive layer comprising a mixture of two adhesives, and/or with a skin permeation enhancer, e.g., in an amount that can significantly enhance the flux of dextromethorphan. The transdermal delivery device can also be characterized by its in vitro and/or in vivo release profile, for example, that can provide a desired pharmacokinetic profile described herein. Also provided herein are methods of administering dextromethorphan, and methods of treating a disease or disorder described herein, using the transdermal delivery device herein.

1 - 29 . (canceled) 
     
     
         30 . A transdermal delivery device comprising (1) an adhesive layer comprising an adhesive, which optionally comprises dextromethorphan dispersed in the adhesive in an amount of about 2% to about 12% by weight of the adhesive layer; and (2) a reservoir layer comprising dextromethorphan in an amount of at least 10% by weight of the reservoir layer. 
     
     
         31 . A transdermal delivery device comprising an adhesive layer comprising dextromethorphan dispersed in an adhesive comprising an acrylate adhesive and a silicone adhesive, wherein the weight ratio of the acrylate adhesive to silicon adhesive ranges from about 20:1 to about 1:20.